‘Ending Paralysis’ Roundtable
Please welcome Dr Lior Shaltiel, CEO and director at NurExone Biologic, to our panel of experts for the ‘Ending Paralysis’ Roundtable on October 13th. Read More
October 19, 2022
Please welcome Dr Lior Shaltiel, CEO and director at NurExone Biologic, to our panel of experts for the ‘Ending Paralysis’ Roundtable on October 13th. Read More
Results show a significant increase in effectiveness of NurExone’s therapeutic compounds in inhibition of PTEN expression Read More
The Future Markets Research Tank (FMRT) is proud to release market commentary on NurExone Biologic (TSXV: NRX) (FSE: J90), an innovative biotechnology company poised to disrupt the spinal cord injury treatment industry and the exosome research landscape Read More
Woher kommt diese Exosome-Technologie? – Wieso gerade jetzt der Börsengang? – Exosome können wir also auch mit Informationen bestücken, wie sie etwas heilen oder reparieren müssen? – Kann man diese Technologie auch gegen Krebs und Tumore verwenden? – Kommen wir zur Querschnittslähmung, hier sind ja die Nervenstränge getrennt. Wie bringe
It is well known that the pandemic caused a sharp rise in the price of tech stocks, which also boosted late-stage startup valuations significantly. This trend benefited startups in many industries, including biotech and e-commerce. In addition to receiving record funding, the number of unicorns increased significantly in 2021 to
NurExone Biologic Ltd. is an Israeli biotech company developing treatment to restore function in patients with traumatic CNS damage. NurExone’s approach is based on a proprietary exosome-based technology with intranasal delivery to revolutionize the treatment of acute spinal cord injury (SCI) worldwide.Read More
Calgary, Alberta–(Newsfile Corp. – October 4, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, announced today results from a controlled survey in the Company’s lab showing the effectiveness of the
NurExone Announces Additional Securities for Debt Settlemen Read More
Under the Letter of Intent, NurExone will explore collaborations with denovoMATRIX to use its advanced screenMATRIX platform to develop specialized coatings for NurExone’s cell carriers for exosome production in order to optimize the manufacturing processes of the non-invasive NurExone’s ExoTherapy. The primary aim of the collaboration is to develop a